Kailera Therapeutics (KLRA) experienced a significant pre-market surge of 5.24% on Tuesday, indicating heightened investor activity before the opening bell.

The sharp upward movement appears to be directly linked to reports of substantial insider buying at the company, which market participants interpret as a strong vote of confidence from those with intimate knowledge of the firm's operations.

Such insider activity often signals to investors that executives and directors believe the stock is undervalued or that positive developments may be on the horizon, leading to increased buying pressure in early trading sessions.